# Safety of L1-79 in Adolescent and Adult Males With Autism

> **NCT02947048** · PHASE2 · COMPLETED · sponsor: **Yamo Pharmaceuticals LLC** · enrollment: 42 (actual)

## Conditions studied

- Autism

## Interventions

- **DRUG:** L1-79
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02947048
- **Lead sponsor:** Yamo Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-12
- **Final completion:** 2018-02-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947048, "Safety of L1-79 in Adolescent and Adult Males With Autism". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02947048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*